TrialBioMed research international2014

Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.

Ki-Seong Eom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.